Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JDVIF
ADC Name
10D7-MMAE
Synonyms
10D7 MMAE; 10D7MMAE
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
4.5-4.7
Antibody Name
Anti-CDCP1 mAb 10D7
  Antibody Info 
Antigen Name
CUB domain-containing protein 1 (CDCP1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI) 
≈ 100
%
Ovarian cancer PDX model (PDX: PH250)
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 24) Positive CDCP1 expression (CDCP1 +++/++)
Method Description
Mice were randomized into groups of six and administered a single intravenous treatment of 10D7 MMAE (5 mg/kg), 10D7 (5 mg/kg), MMAE (0.17 mg/kg; equivalent to a four molar excess of the 10D7-MMAE dose) or vehicle.
In Vivo Model Ovarian cancer PDX model (PDX: PH250)
References
Ref 1 Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer. Theranostics. 2020 Jan 12;10(5):2095-2114. doi: 10.7150/thno.30736. eCollection 2020.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.